Close

Press Releases

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment. Inflammation...

Vesigen Therapeutics launches with USD 28.5 million Series A investment led by Leaps by Bayer and Morningside Ventures

Vesigen Therapeutics launched with the objective to overcome the hurdle of targeted intracellular drug delivery of next-generation therapeutics, such as CRISPR-cas9, RNA molecules and other therapeutic proteins, by using a proprietary delivery technology. Leaps by Bayer and Morningside Ventures...

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA in Patients Treated with Zolgensma

Biogen Inc announced it plans to initiate a global Phase 4 clinical study, RESPOND, to examine the clinical benefit and assess the safety of SPINRAZA® (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet...

Catalent Biologics to Invest $30 Million to Create European Clinical Manufacturing Center of Excellence in France

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it plans to invest $30 million (€27 million) at its facility in Limoges,...

GSK and CureVac announce strategic mRNA technology collaboration

GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA...

Stevanato Group signs an agreement with COLANAR for lab-scale fill & finish capabilities

Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for drug delivery systems has signed an agreement with COLANAR, a global leader in small-batch pharma filling machines. Stevanato Group's new US Technology Excellence Center...

Thermo Fisher Scientific Launches Industry-Leading Offering to Facilitate cGMP-Compatible Cell and Gene Therapy Manufacturing

Thermo Fisher Scientific announces the launch of an industry-leading product, compliance and services portfolio, compatible with current Good Manufacturing Practice (cGMP) and designed to enable rapid start-up of clinical and commercial cell and gene therapy manufacturing. Developed as the first-ever...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »